Organic acids and derivatives
Medchemexpress LLC Sevelamer carbonate | 845273-93-0 | 100 MG
Sevelamer carbonate is an orally active, non-calcium-based phosphate binding agent for hyperphosphatemia associated with chronic kidney disease (CKD). It effectively reduces serum phosphorus levels with minimal impact on serum calcium or chloride. This improved, buffered form of sevelamer decreases serum levels of gut-derived uremic toxins, reduces serum phosphate, and lowers low-density lipoprotein cholesterol. It may also cause less metabolic acidosis than sevelamer hydrochloride in vivo.
- Phosphate binding agent: orally active, non-calcium-based, lowers serum phosphorus.
- Minimal impact on serum calcium or chloride levels.
- Improved, buffered sevelamer formulation.
- Reduces gut-derived uremic toxins.
- Lowers LDL cholesterol.
- May cause less metabolic acidosis.
Medchemexpress LLC Sevelamer (carbonate) | 845273-93-0 | 25 G
Sevelamer carbonate is an orally active and non-calcium-based phosphate binding agent used for research on hyperphosphatemia of chronic kidney disease (CKD). It effectively lowers serum phosphorus levels with minimal effect on serum calcium or serum chloride levels in vivo. It is considered an improved, buffered form of sevelamer. This product is intended for laboratory use in the manufacture of substances and is not classified as a hazardous substance or mixture.
- Orally active and non-calcium-based phosphate binding agent
- Used for research on hyperphosphatemia of chronic kidney disease (CKD)
- Effectively lowers serum phosphorus levels
- Minimal effect on serum calcium or serum chloride levels in vivo
- Stable under recommended storage conditions
- For research use only
Medchemexpress LLC Sevelamer (carbonate) | 845273-93-0 | 500 MG
Sevelamer carbonate is an orally active, non-calcium-based phosphate binding agent primarily used in research for managing hyperphosphatemia in chronic kidney disease (CKD). It effectively lowers serum phosphorus levels while maintaining minimal impact on serum calcium or chloride levels. This buffered form of sevelamer functions as an anion-exchange resin, sharing the polymeric structure of sevelamer hydrochloride, but with carbonate substituting chloride.
- Orally active, non-calcium-based phosphate binding agent
- Lowers serum phosphorus levels effectively
- Minimal effect on serum calcium or chloride levels
- Improved, buffered form of sevelamer
- May cause less metabolic acidosis
- Associated with decreased low-density lipoprotein cholesterol levels
- Decreases serum levels of gut-derived uremic toxins (in vitro)
- Reduces serum phosphate levels in Npt2b-deficient mice (in vivo)